Global Immuno-oncology Drugs Market

Immuno-oncology Drugs Market is expected to reach US$ 110.75 Bn. by 2032 at a CAGR of 17.83% during 2026-2032.

Immuno-oncology Drugs Market Overview:

Immuno-oncology is the artificial stimulation of the immune system to treat cancer, improving the immune system's ability to fight the disease. This needs to be personalized because anticancer immune responses can be inhibited in several ways that vary from patient to patient.

Global Immuno-oncology Drugs Market Dynamics:

Technological developments are expected to boost the Immuno-oncology drugs market.

To know about the Research Methodology :- Request Free Sample Report

Immuno-oncology is considered to be a promising therapy in treating cancer owing to the recent developments in drug discovery and development. The growing number of Immuno-oncology treatments, which are in different phases of clinical trials, and the increasing approval of Immuno-oncology therapies by the FDA are leading to the acceptance of new and advanced technologies in the field of Immuno-oncology therapy. These factors help in propelling the market growth.

The increasing prevalence of cancer patients globally serves to be the primary growth factor for the Immuno-oncology drugs market. The rising adoption of immunotherapies over the traditional chemotherapies, increase in popularity of advanced therapies (biological and targeted drug therapies), and surge in the geriatric population worldwide are the key factors driving the growth of the market. According to the WHO, cancer is the second leading cause of death worldwide and an estimated 9.6 million deaths in 2018.

The approval of therapeutic solutions in the Immuno-Oncology segment is poised to rapidly increase due to the growing recognition of durable tumour responses. Hence, the competition between pharmaceutical players is intensifying as they strive to achieve first-mover advantages in specific medical applications. However, the high cost involved in new drug development and the threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market.

The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.

Global Immuno-oncology Drugs Market Segment Analysis:

The Global Immuno-oncology Drugs Market is segmented on the basis of Drug Type, Application and End-Users.

Based on Drug Type, the immune checkpoint inhibitors segment is expected to hold a dominant market share and along with this, the CAR T cell therapy segment is expected to witness lucrative growth during the forecast period. The immune checkpoint inhibitors have had remarkable success across multiple malignancies, and are the most well-established therapeutic class of Immuno-oncology agents to date.

The CAR T Cell Therapy segment is expected to witness lucrative growth during the forecast period. The rising prevalence of cancer and demand for effective treatment is considered to be the major drivers for the segment growth. In May 2020, researchers from University Hospital Heidelberg, Germany, reported that sufficient yield of lymphocytes for CAR-T cell production is feasible also for patients with low peripheral blood counts.

Immuno-oncology Drugs Market Regional Insights:

North America is expected to hold a larger market share, followed by Europe during forecast years.

The Region is experiencing exponential growth over the last 5 years. It accounted for a market share of xx% in 2025 and is experiencing a continuous increase since then. The commercial success is attributed to multiple factors, including speed-to-market, clinical & commercial positioning, marketing approach, and patient group targeting.

In recent times, pharma companies are turning to Immuno-Oncology to address some of the most pressing challenges in curing cancer. Various national and international conferences are being arranged such as the Clinical Immuno-Oncology Symposium in Orlando, Florida, organized by ASCO and SITC (Society for Immunotherapy and Cancer), where Scientists, pharma companies, and global healthcare organizations are exchanging research results.

Asia Pacific is expected as the fastest-growing region during the forecast period at a CAGR of xx%.

The Asia Pacific will command the global market owing to the drivers like improved medical infrastructure, increased patient awareness and rise in disposable income. Cancers with high somatic mutations such as melanoma, lung, bladder, stomach or oesophageal cancer are known to be more responsive to immunotherapies. These cancers are highly prevalent in the Asia-Pacific region.

The report also helps in understanding the Global Immuno-oncology Drugs Market dynamics, structure by analyzing the market segments and project the Global Immuno-oncology Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Immuno-oncology Drugs Market make the report investor’s guide.

Global Immuno-oncology Drugs Market Key developments:

Global Immuno-oncology Drugs Market Scope: Inquire before buying

Global Immuno-oncology Drugs Market, by Region:

• North America
• Europe
• South America
• MEA
• APAC

Global Immuno-oncology Drugs Market Key players:

1. Amgen Inc.
2. AstraZeneca Plc
3. Bristol Myers Squibb Company
4. AbbVie Inc.
5. Eli Lilly and Company
6. Sanofi
7. F. Hoffmann-La Roche Ltd.
8. Genentech, Inc.
9. Novartis AG
10. Pfizer Inc.
11. Johnson & Johnson
12. Merck & Co., Inc.
13. Merck KGaA
14. GSK Plc
15. Regeneron Pharmaceuticals, Inc.
16. Bayer AG
17. Ipsen
18. Bluebird Bio, Inc.
19. Agenus Inc.
20. BeiGene Ltd.
21. Incyte Corporation
22. Seagen Inc.
23. Moderna, Inc.
24. BioNTech SE
25. Exelixis, Inc.
Others